GB0609117D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB0609117D0
GB0609117D0 GBGB0609117.7A GB0609117A GB0609117D0 GB 0609117 D0 GB0609117 D0 GB 0609117D0 GB 0609117 A GB0609117 A GB 0609117A GB 0609117 D0 GB0609117 D0 GB 0609117D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0609117.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotica Technology Ltd
Original Assignee
Biotica Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotica Technology Ltd filed Critical Biotica Technology Ltd
Priority to GBGB0609117.7A priority Critical patent/GB0609117D0/en
Publication of GB0609117D0 publication Critical patent/GB0609117D0/en
Priority to US12/296,537 priority patent/US20100068203A1/en
Priority to BRPI0711092-8A priority patent/BRPI0711092A2/pt
Priority to EP07728925A priority patent/EP1940798A1/en
Priority to JP2009508382A priority patent/JP2009536934A/ja
Priority to PCT/EP2007/054473 priority patent/WO2007128827A1/en
Priority to CNA2007800165888A priority patent/CN101437802A/zh
Priority to KR1020087027546A priority patent/KR20090005377A/ko
Priority to AU2007247119A priority patent/AU2007247119A1/en
Priority to CA002651557A priority patent/CA2651557A1/en
Priority to MX2008014279A priority patent/MX2008014279A/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
GBGB0609117.7A 2006-05-09 2006-05-09 Novel compounds Ceased GB0609117D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB0609117.7A GB0609117D0 (en) 2006-05-09 2006-05-09 Novel compounds
MX2008014279A MX2008014279A (es) 2006-05-09 2007-05-09 Derivados de 17-oximacbecina y su uso en el tratamiento de cancer y/o malignidades de celula b.
JP2009508382A JP2009536934A (ja) 2006-05-09 2007-05-09 １７−オキシマクベシン誘導体並びに癌及び／又はｂ−細胞性悪性疾患の治療におけるそれらの使用
BRPI0711092-8A BRPI0711092A2 (pt) 2006-05-09 2007-05-09 composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um análogo de 17-oximacbecina, métodos de tratamento de doenças, e para a produção de um análogo de 17-oximacbecina,cepa hospedeira,processo para produzir 17-oximacbecina ou um análogo do mesmo, e, uso de uma cepa hospedeira
EP07728925A EP1940798A1 (en) 2006-05-09 2007-05-09 17-oxymacbecin derivatives and their use in the treatment of cancer and/or b-cell malignancies
US12/296,537 US20100068203A1 (en) 2006-05-09 2007-05-09 17-Oxymacbecin Derivatives and Their Use in the Treatment of Cancer and/or B-Cell Malignancies
PCT/EP2007/054473 WO2007128827A1 (en) 2006-05-09 2007-05-09 17-oxymacbecin derivatives and their use in the treatment of cancer and/or b-cell malignancies
CNA2007800165888A CN101437802A (zh) 2006-05-09 2007-05-09 17-氧基麦克菌素衍生物及其在癌症和/或b-细胞恶性肿瘤的治疗中的用途
KR1020087027546A KR20090005377A (ko) 2006-05-09 2007-05-09 17-옥시막베신 유도체 및 이의 암 및/또는 ｂ-세포 악성종양 치료 용도
AU2007247119A AU2007247119A1 (en) 2006-05-09 2007-05-09 17-oxymacbecin derivatives and their use in the treatment of cancer and/or B-cell malignancies
CA002651557A CA2651557A1 (en) 2006-05-09 2007-05-09 17-oxymacbecin derivatives and their use in the treatment of cancer and/or b-cell malignancies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0609117.7A GB0609117D0 (en) 2006-05-09 2006-05-09 Novel compounds

Publications (1)

Publication Number Publication Date
GB0609117D0 true GB0609117D0 (en) 2006-06-21

Family

ID=36637122

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0609117.7A Ceased GB0609117D0 (en) 2006-05-09 2006-05-09 Novel compounds

Country Status (11)

Country Link
US (1) US20100068203A1 (enExample)
EP (1) EP1940798A1 (enExample)
JP (1) JP2009536934A (enExample)
KR (1) KR20090005377A (enExample)
CN (1) CN101437802A (enExample)
AU (1) AU2007247119A1 (enExample)
BR (1) BRPI0711092A2 (enExample)
CA (1) CA2651557A1 (enExample)
GB (1) GB0609117D0 (enExample)
MX (1) MX2008014279A (enExample)
WO (1) WO2007128827A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160175A1 (en) * 2006-09-11 2011-06-30 Christine Martin 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer
US9967590B2 (en) 2008-04-10 2018-05-08 Qualcomm Incorporated Rate-distortion defined interpolation for video coding based on fixed filter or adaptive filter
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CN110999828A (zh) * 2019-12-19 2020-04-14 上海海洋大学 改变鱼类体色分布模式的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2146668A1 (en) * 1992-10-14 1994-04-28 Luke Whitesell Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies
EP0828418A4 (en) * 1995-05-02 2000-03-29 Univ California INDUCTION OF THERMOTOLERANCE WITH BENZOCHINOIDS ANSAMYCINES

Also Published As

Publication number Publication date
WO2007128827A8 (en) 2008-01-03
US20100068203A1 (en) 2010-03-18
MX2008014279A (es) 2008-11-26
CA2651557A1 (en) 2007-11-15
EP1940798A1 (en) 2008-07-09
JP2009536934A (ja) 2009-10-22
BRPI0711092A2 (pt) 2011-08-23
WO2007128827A1 (en) 2007-11-15
KR20090005377A (ko) 2009-01-13
AU2007247119A1 (en) 2007-11-15
CN101437802A (zh) 2009-05-20

Similar Documents

Publication Publication Date Title
EP2034838A4 (en) NOVEL CONNECTIONS
EP2032142A4 (en) NOVEL CONNECTIONS
EP1981596A4 (en) NEW CONNECTIONS
EP1981900A4 (en) NEW COMPOUNDS
GB0603550D0 (en) Novel compounds
GB0609962D0 (en) Novel compounds
GB0605462D0 (en) Novel compounds
GB0602900D0 (en) Novel Compounds
EP2031965A4 (en) NEW COMPOUNDS
GB0609117D0 (en) Novel compounds
GB0609963D0 (en) Novel compounds
GB0607840D0 (en) Novel compounds
GB0607892D0 (en) Novel compounds
GB0600483D0 (en) Novel compounds
GB0609252D0 (en) Novel sytoprotective compounds
GB0608452D0 (en) Novel compounds
GB0608457D0 (en) Novel compounds
GB0601288D0 (en) Novel compounds
GB0608976D0 (en) Novel compounds
GB0602047D0 (en) Novel compounds
GB0608567D0 (en) Novel compounds
GB0608978D0 (en) Novel compounds
GB0608566D0 (en) Novel compounds
GB0606549D0 (en) Novel compounds
GB0608455D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)